FDA Approves Brentuximab for Cutaneous T-Cell Lymphoma FDA Approves Brentuximab for Cutaneous T-Cell Lymphoma
The drug had significant advantages over two other currently used agents in a phase 3 clinical trial.FDA Approvals
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
More News: Cancer & Oncology | Clinical Trials | Cutaneous T cell lymphoma | Health | Hematology | Lymphoma | T-cell Lymphoma